Crucell's mission is to develop, produce and market vaccines and antibodies that prevent or treat infectious diseases.
€283.3m - Total revenue and other operating income in 2008 45% - Gross margin in 2008 €14.6m - Net profit in 2008

Overview

“In 2008, Crucell’s vaccines were administered to a vast number of people worldwide, thereby preventing more than 3 million cases of infectious disease and over 700,000 deaths that would otherwise have occurred.”

Ronald H.P. Brus President and Chief Executive Officer